Co-Diagnostics, Inc. to Present at the Lytham Partners Virtual Investor Conference on November 30, 2017 at 2:00 p.m. ET

Management to Review Investor Presentation and Conduct Q&A; Replay Available on Demand

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced that Dwight Egan, chief executive officer of Co-Diagnostics, will present at the Lytham Partners Virtual Investor Conference on Thursday, November 30, 2017 at 2:00 p.m. ET (11:00 a.m. PT). The conference is a virtual event available over the internet, and interested parties may participate by following any of the links below at the time of the conference.

Event:Lytham Partners Virtual Investor Conference
Date:November 30, 2017
Time:

2:00 p.m. ET / 11:00 a.m. PT

Webcast:

http://ir.codiagnostics.com/events-and-presentations or  http://www.lythampartners.com/vic.aspx, or by accessing the link here.

Interested parties around the world may view the live investor presentation and ask the speakers questions in real time.

A replay of the presentation will be available on demand following the conclusion of the live event at http://ir.codiagnostics.com/events-and-presentations or http://www.lythampartners.com/vic.aspx, or by accessing the link here.

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.

Forward-Looking Statements

With the exception of historical information, the content in this press release and the virtual investor conference referred to in this communication, may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. Risks, uncertainties and other factors are discussed in the Company’s filings with the U.S. Securities and Exchange Commission on Annual Report Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Contacts

Company Contact:
Co-Diagnostics, Inc.
Andrew Benson, Investor Relations
801-438-1036
investors@codiagnostics.com
or
Investor Contact:
Lytham Partners
Joe Diaz, Robert Blum, Joe Dorame
602-889-9700
codx@lythampartners.com

Original Press Release found here.